<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190701044064N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-09-14</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Okra in Diabetes</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Efficacy  of Okra powder mixed with Yogurt and Yogurt in Controlling Fasting Blood Glucose (FBS) in Patients with Type 2 Diabetes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/40544</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this Double-blind Study, We Selected 60 Outpatients with type 2 Diabetes who were referred to Diabetes Clinics based on entry Criteria, and then Randomly divided into two groups of 30 adolescents, Blinding description: This is a double-blind, randomized, double-blind, clinical trial of 60 patients with type 2 diabetes who are referred to the diabetes center for a period of 8 weeks. The patient was visited by a doctor at her first visit to the treatment centers. A form of willingness to participate in the intervention is taken from the written consent form. Patients are requested to fill out a form for evaluating entry criteria.For this study 200 kilograms of okra have been purchased. After washing, drying and grinding, and then in 10 grams packages, the milk and yogurt factory will be delivered to 150 grams of yogurt, and it is recommended to patients to mix mixed yogurt After lunch or dinner, take daily oatmeal everyday.
In this study, simple yogurt was used as a placebo.
Patients are advised to spend their yogurt after lunch or dinner. In this study, the investigator will be unaware of the fact that the yogurt is given to the patient or the yoghurt is unaware and the nurse is only aware that the person is based on that Which group contains the drug or the placebo? Also, the analyst is also well aware.</study_design>
      <phase>0 (exploratory trials)</phase>
      <hc_freetext>Diabet.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Okra plant will be supplied with a scientific name of 200 kilograms of greens. After collecting and rinsing, the okra was completely dried in dry conditions for several days, and after preparing dried okra powder, it was packed in 10 grams and delivered to the milk and yogurt factory, and the factory supplied 150 grams of yogurt Mix 10 grams of okra powder and mix the yogurt with okra after your main meal, lunch or dinner. Intervention 2: Control group: This group is recommended to eat 150g yogurt after their main meal, lunch or dinner.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only part of the data, such as the key outcome information or the like, can share.

When:
Start period of 3 months after publication of the article

To whom:
Researchers at academic and academic institutions

Conditions:
Research

Where to obtain:
Arezoo moradi
 Contact number 09140613368,
Address: Kerman- Rafsanjan Town of Thousand Units of Imam Ali Street
Postal Code 7713166116

How to obtain:
Academic Requests

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyyed Morteza Safavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Hezar Jarib Street, Isfahan, Iran</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7713166116</zip>
        <telephone>+98 317923164</telephone>
        <email>moradi8028@yahoo.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Arezoo Moradi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 23, Imam Ali Street 9, Thousand Unit Settlement</address>
        <city>Rafsanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7713166116</zip>
        <telephone>+98 34 3429 2292</telephone>
        <email>moradi8028@yahoo.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Taking Oral Anti Diabetic Medicine
No Pregnancy
Lack of Alcohol
Do not Take Anti Hypertensive Medication
No Smoking
Not Taking Herbal Supplement to Control Blood Glucose
Non Lactation in Women
Not Getting Kidney Disease, Especially Diabetic Nephropathy</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Okra Sensitivity
Get Pregnant
Unwillingness to Cooperate</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I00-I99</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diseases of the circulatory system</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Okra plant will be supplied with a scientific name of 200 kilograms of greens. After collecting and rinsing, the okra was completely dried in dry conditions for several days, and after preparing dried okra powder, it was packed in 10 grams and delivered to the milk and yogurt factory, and the factory supplied 150 grams of yogurt Mix 10 grams of okra powder and mix the yogurt with okra after your main meal, lunch or dinner.</i_keyword>
      <i_keyword>Control group: This group is recommended to eat 150g yogurt after their main meal, lunch or dinner</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fasting blood glucose. Timepoint: The beginning and the end of the study. Method of measurement: Biochemical method.</prim_outcome>
      <prim_outcome>Serum LDL-C. Timepoint: The beginning and the end of the study. Method of measurement: Biochemical method.</prim_outcome>
      <prim_outcome>HDL-C Serum. Timepoint: The beginning and the end of the study. Method of measurement: Biochemical method.</prim_outcome>
      <prim_outcome>TG Serum. Timepoint: The beginning and the end of the study. Method of measurement: Biochemical method.</prim_outcome>
      <prim_outcome>Total cholesterol. Timepoint: The beginning and the end of the study. Method of measurement: Biochemical method.</prim_outcome>
      <prim_outcome>Hemoglobin A1c. Timepoint: The beginning and the end of the study. Method of measurement: Biochemical method.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Blood pressure. Timepoint: The beginning and the end of the study. Method of measurement: Blood pressure monitor.</sec_outcome>
      <sec_outcome>Weight. Timepoint: The beginning and the end of the study. Method of measurement: digital Balance.</sec_outcome>
      <sec_outcome>Age. Timepoint: Beginning of study. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Sex. Timepoint: Beginning of study. Method of measurement: questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-01-25</approval_date>
        <contact_name>Isfahan Medical Ethics Committee</contact_name>
        <contact_address>Isfahan University of Medical Sciences. Isfahan Nutrition and Food Sciences Faculty Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
